斑蝥酸钠联合化疗方案对非小细胞肺癌患者microRNA-21与SIRT1表达影响的研究

Study on Effect of microRNA-21 and SIRT1 Expression on Sodium Cantharidinate Combined Chemotherapy Scheme in Patients with Non-small Cell Lung Cancer

为研究斑蝥酸钠联合化疗方案治疗非小细胞肺癌患者疗效,分析其对microRNA-21与SIRT1表达的影响。本研究将86例晚期非小细胞肺癌患者依据数字随机法平均分为两组:对照组采用紫杉醇加顺铂化疗,观察组采用斑蝥酸钠联合紫杉醇加顺铂化疗,比较两组患者治疗疗效及microRNA-21与SIRT1表达量变化情况。观察组治疗有效率67.4%,显著高于对照组(44.2%)(字2=4.71,p=0.03);非小细胞肺癌患者癌组织中的microRNA-21表达量为(4.67±1.25),显著高于癌旁组织表达量为(2.45±1.08)(t=8.81,p=0.00);非小细胞肺癌患者癌组织中SIRT1表达阳性率为62.8%(39.5%~76.4%),显著高于癌旁组织表达率为42.5%(25.1%~54.1%)(t=10.94,p<0.05);治疗前,两组患者癌组织中microRNA-21表达量和SIRT1表达阳性率(%)无统计学差异(p>0.05),经治疗后均显著下降(p<0.05),但观察组下降程度显著高于对照组(p<0.05);治疗后观察组免疫功能指标显著升高,且观察组治疗后CD^(4+)/CD^(8+)和NK细胞显著高于对照组(p<0.05);观察组临床症状改善情况和生活质量改善程度均优于对照组,差异具有统计学意义(p<0.05);观察组胃肠道反应率和白细胞下降率分别为13.9%和9.3%,对照组分别为39.5%和30.2%,两组差异具有统计学意义(p<0.05)。由此得出结论,斑蝥酸钠联合化疗方案治疗非小细胞肺癌患者,能够有效抑制microRNA-21和SIRT1的表达,提高治疗疗效,改善患者生活质量和免疫功能,降低不良反应率,具有增效减毒的作用,从而改善预后。

To investigate the cantharidin sodium combined with chemotherapy efficacy in patients with non-small cell lung cancer and analyze its effects on microRNA-21 and SIRT 1 expression, 86 cases of advanced non-small cell lung cancer patients based on average figures randomly divided into two groups： the control group, paclitaxel plus cisplatin, observation group cantharidin sodium combined with paclitaxel plus cisplatin, compare two groups of patients the efficacy and microRNA-21 and SIRT 1 expression changes. The treatment efficiency of 67.2%, signifi- cantly higher （44.2%） （χ2=4.71, p =0.03）; non-small cell lung carcinoma patients microRNA-21 expression levels （4.67± 1.25）, significantly higher than the adjacent tissues expression levels （2.45± 1.08） （t=8.81, p =0.00）; non-small cell lung carcinoma patients SIRT1 expression was 62.8% （39.5%-76.4%） was significantly higher than cancerous tissue expression rate of 42.5% （25.1%-54.1%） （t= 10.94, p 〈0.05）; Before treatment, patients were carcinoma microRNA-21 expression and SIRT1 expression rate （%） was not statistically difference （p 〉0.05）, after treatment were significantly decreased （p〈0.05）, but the degree of decline in the observation group was significantly higher （p 〈0.05）; significantly increased immune function parameters in the observation group after treatment, and the observation group after the CD4＋/CD8＋ and NK cells were significantly higher （p〈0.05）; improvement of clinical symptoms was observed, and the degree of improvement of quality of life than the control group, the difference was statistically significant （p 〈0.05）; gastrointestinal observation group road reaction rate and leukopenia rates were 13.9% and 9.3% in the control group were 39.5% and 30.2%, the difference was statistically significant （/）〈0.05）. The results showed that sodium Cantharidinate chemotherapy in the treatment of non-small cell lung cancer, can inhibit microRNA-21 expression and SIRT 1, improve treatment efficacy, improve patient quality of life and immu- ne function, reduce the rate of adverse reactions and have a synergistic role attenuated, thereby improving prognosis.